Inmune Bio Stock Today
| INMB Stock | USD 2.42 0.18 8.04% |
PerformanceVery Weak
| Odds Of DistressLow
|
INmune Bio is trading at 2.42 as of the 21st of July 2025, a 8.04 percent increase since the beginning of the trading day. The stock's open price was 2.24. INmune Bio has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of April 2025 and ending today, the 21st of July 2025. Click here to learn more.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 27.24 M outstanding shares of which 10.43 M shares are currently shorted by private and institutional investors with about 16.36 trading days to cover. More on INmune Bio
Moving against INmune Stock
INmune Stock Highlights
INmune Bio (INMB) is traded on NASDAQ Exchange in USA. It is located in 225 NE Mizner Blvd., Boca Raton, FL, United States, 33432 and employs 13 people. INmune Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.92 M. INmune Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.24 M outstanding shares of which 10.43 M shares are currently shorted by private and institutional investors with about 16.36 trading days to cover.
INmune Bio currently holds about 61.21 M in cash with (33.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check INmune Bio Probability Of Bankruptcy
Ownership AllocationINmune Bio has a total of 27.24 Million outstanding shares. INmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check INmune Ownership Details
INmune Bio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. INmune Bio market risk premium is the additional return an investor will receive from holding INmune Bio long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (2.46) | |||
| Treynor Ratio | 0.713 |
INmune Stock Against Markets
INmune Bio Corporate Management
| Christopher Barnum | Head Neuroscience | Profile | |
| BSc FRCPath | Chief Officer | Profile | |
| Mark Lowdell | Chief Officer | Profile | |
| Raymond MD | President, CoFounder | Profile | |
| Joshua Esq | General Counsel | Profile | |
| David MBA | Treasurer CFO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.